Meda and EMD Consolidated Pension Plan

Viatris Inc. is the plan sponsor. Viatris was formed in 2020 through the merger of Mylan N.V. and Pfizer's Upjohn business. The consolidated pension plan covers liabilities from several Viatris-related employers, including Mylan Specialty L.P. and EMD Inc.

The portfolio is structured via a fund-of-funds approach. Known allocations include a mixed-use real estate portfolio and a hedge fund sleeve. No direct private equity or venture capital positions have been publicly identified.

No. It is a private-sector pension fund that consolidates defined-benefit liabilities for employees of several pharmaceutical companies that are now part of Viatris. It does not manage personal wealth for any founding family.

Yes. The fund-of-funds structure implies the plan invests through external managers rather than making direct asset-level investments. The specific manager roster is not publicly reported.

The plan's assets originate from contributions made by the sponsor and participating employers — principally Viatris and its predecessor entities Mylan, Meda AB, and Alpharma — to fund defined-benefit promises for current and former pharmaceutical workers.

There is no public evidence of a philanthropic foundation or operating business directly tied to the pension plan. Viatris runs corporate responsibility programs, but those are distinct from the plan's fiduciary investment activities.

As an internal corporate vehicle, the plan does not source deals like a family office or venture firm. It likely conducts manager selection and allocation decisions through Viatris's treasury or investment committee, though the specific governance framework has not been disclosed.